AKBLF
Price
$20.30
Change
-$2.05 (-9.17%)
Updated
Jan 8 closing price
Capitalization
4.61B
IOVA
Price
$5.91
Change
+$0.15 (+2.60%)
Updated
Jan 17 closing price
Capitalization
1.8B
38 days until earnings call
Ad is loading...

AKBLF vs IOVA

Header iconAKBLF vs IOVA Comparison
Open Charts AKBLF vs IOVABanner chart's image
Alk Abello AS
Price$20.30
Change-$2.05 (-9.17%)
Volume$1
Capitalization4.61B
Iovance Biotherapeutics
Price$5.91
Change+$0.15 (+2.60%)
Volume$6.56M
Capitalization1.8B
AKBLF vs IOVA Comparison Chart
Loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBLF vs. IOVA commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBLF is a Hold and IOVA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (AKBLF: $20.30 vs. IOVA: $5.91)
Brand notoriety: AKBLF and IOVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBLF: 1% vs. IOVA: 85%
Market capitalization -- AKBLF: $4.61B vs. IOVA: $1.8B
AKBLF [@Biotechnology] is valued at $4.61B. IOVA’s [@Biotechnology] market capitalization is $1.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBLF’s FA Score shows that 0 FA rating(s) are green whileIOVA’s FA Score has 0 green FA rating(s).

  • AKBLF’s FA Score: 0 green, 5 red.
  • IOVA’s FA Score: 0 green, 5 red.
According to our system of comparison, IOVA is a better buy in the long-term than AKBLF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBLF’s TA Score shows that 1 TA indicator(s) are bullish while IOVA’s TA Score has 4 bullish TA indicator(s).

  • AKBLF’s TA Score: 1 bullish, 3 bearish.
  • IOVA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, IOVA is a better buy in the short-term than AKBLF.

Price Growth

AKBLF (@Biotechnology) experienced а 0.00% price change this week, while IOVA (@Biotechnology) price change was -7.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

IOVA is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBLF($4.61B) has a higher market cap than IOVA($1.8B). AKBLF YTD gains are higher at: -9.172 vs. IOVA (-20.135). AKBLF has higher annual earnings (EBITDA): 1.34B vs. IOVA (-388.32M). AKBLF has more cash in the bank: 556M vs. IOVA (397M). IOVA has less debt than AKBLF: IOVA (78.9M) vs AKBLF (510M). AKBLF has higher revenues than IOVA: AKBLF (5.38B) vs IOVA (90.9M).
AKBLFIOVAAKBLF / IOVA
Capitalization4.61B1.8B256%
EBITDA1.34B-388.32M-346%
Gain YTD-9.172-20.13546%
P/E Ratio42.01N/A-
Revenue5.38B90.9M5,922%
Total Cash556M397M140%
Total Debt510M78.9M646%
FUNDAMENTALS RATINGS
AKBLF vs IOVA: Fundamental Ratings
AKBLF
IOVA
OUTLOOK RATING
1..100
5059
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
56100
SMR RATING
1..100
5297
PRICE GROWTH RATING
1..100
5891
P/E GROWTH RATING
1..100
86100
SEASONALITY SCORE
1..100
5585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IOVA's Valuation (43) in the Biotechnology industry is somewhat better than the same rating for AKBLF (82) in the null industry. This means that IOVA’s stock grew somewhat faster than AKBLF’s over the last 12 months.

AKBLF's Profit vs Risk Rating (56) in the null industry is somewhat better than the same rating for IOVA (100) in the Biotechnology industry. This means that AKBLF’s stock grew somewhat faster than IOVA’s over the last 12 months.

AKBLF's SMR Rating (52) in the null industry is somewhat better than the same rating for IOVA (97) in the Biotechnology industry. This means that AKBLF’s stock grew somewhat faster than IOVA’s over the last 12 months.

AKBLF's Price Growth Rating (58) in the null industry is somewhat better than the same rating for IOVA (91) in the Biotechnology industry. This means that AKBLF’s stock grew somewhat faster than IOVA’s over the last 12 months.

AKBLF's P/E Growth Rating (86) in the null industry is in the same range as IOVA (100) in the Biotechnology industry. This means that AKBLF’s stock grew similarly to IOVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBLFIOVA
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
21%
Bullish Trend 12 days ago
83%
Momentum
ODDS (%)
Bearish Trend 12 days ago
38%
Bearish Trend 12 days ago
80%
MACD
ODDS (%)
Bearish Trend 12 days ago
44%
Bullish Trend 12 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
33%
Bearish Trend 12 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
21%
Bearish Trend 12 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 12 days ago
86%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 12 days ago
10%
Bearish Trend 12 days ago
88%
View a ticker or compare two or three
Ad is loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DLACX15.460.14
+0.91%
BNY Mellon Large Cap Equity Y
HAIAX53.430.47
+0.89%
Hartford Core Equity A
GTSDX9.550.05
+0.53%
Invesco Small Cap Growth C
MIOLX25.940.06
+0.23%
Morgan Stanley Inst International Opp L
UNWPX1.57N/A
N/A
US Global Investors World Prec Mnral

AKBLF and

Correlation & Price change

A.I.dvisor tells us that AKBLF and MNPR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKBLF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBLF
1D Price
Change %
AKBLF100%
N/A
MNPR - AKBLF
29%
Poorly correlated
-6.36%
MSCLF - AKBLF
27%
Poorly correlated
+1.17%
IOVA - AKBLF
26%
Poorly correlated
+2.60%
SMMT - AKBLF
25%
Poorly correlated
+4.62%
VBIZF - AKBLF
24%
Poorly correlated
N/A
More

IOVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IOVA has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if IOVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IOVA
1D Price
Change %
IOVA100%
+2.60%
CRSP - IOVA
49%
Loosely correlated
+0.57%
VTYX - IOVA
44%
Loosely correlated
+6.88%
VCYT - IOVA
43%
Loosely correlated
-1.27%
AKRO - IOVA
42%
Loosely correlated
+4.71%
ALDX - IOVA
41%
Loosely correlated
+1.26%
More